NCT02749708: Study of IRX5183 in Relapsed and Refractory Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome |
|
|
| Terminated | 1/2 | 13 | US | IRX5183 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Io Therapeutics | Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML) | 08/18 | 08/18 | | |
